Pharvaris (NASDAQ:PHVS) Shares Climb 7.4% – Time to Buy?

Pharvaris N.V. (NASDAQ:PHVS) shares shot up 7.4% on Monday. The company traded as high as $29.79 and last traded at $29.7880. Approximately 555,460 shares were traded during mid-day trading, an increase of 26% from the average session volume of 439,233 shares. The stock had previously closed at $27.74.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PHVS. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Tuesday, October 6th. Morgan Stanley raised their price objective on Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Leerink Partners lifted their price objective on Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Finally, Wells Fargo & Company boosted their target price on Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $58.60.

Pharvaris Trading Up 7.4%

The stock has a market capitalization of $1.95 billion, a PE ratio of -9.74 and a beta of -2.46. The business’s 50-day moving average is $34.41 and its two-hundred day moving average is $32.47.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, analysts predict that Pharvaris N.V. will post -3.12 EPS for the current year.

Insider Buying and Selling at Pharvaris

In related news, Director Johannes Gerardus Chri Schikan sold 800 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $36.19, for a total transaction of $28,952.00. Following the transaction, the director directly owned 115,167 shares of the company’s stock, valued at approximately $4,167,893.73. The trade was a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Peng Lu sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $3,500,000.00. Following the transaction, the president directly owned 64,953 shares in the company, valued at $2,273,355. This trade represents a 60.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 513,102 shares of company stock worth $18,643,666.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new stake in shares of Pharvaris during the second quarter valued at about $1,143,000. Amundi lifted its stake in shares of Pharvaris by 61.4% in the second quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after acquiring an additional 18,992 shares in the last quarter. Moore Capital Management LP acquired a new position in shares of Pharvaris in the second quarter worth about $1,522,000. Alyeska Investment Group L.P. lifted its stake in shares of Pharvaris by 225.5% in the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after acquiring an additional 281,829 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after purchasing an additional 274,034 shares during the last quarter.

About Pharvaris

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.